Anavex Partners with Neuronetrix for Alzheimer’s Clinical Trial

Anavex Partners with Neuronetrix for Alzheimer’s Clinical Trial

senior guide memory lossA novel, potentially disease-modifying treatment for Alzheimer's disease is set to begin a Phase 2a clinical trial, designed to evaluate efficacy over a time frame of 6 months, across 7 study sites in Australia. ANAVEX 2-73, a pipeline product of Anavex Life Sciences Corp.

Subscribe or to access all post and page content.